Thursday, April 18, 2024

Creating liberating content

Oracle Corp’s (NYSE: ORCL)...

Oracle Corp (NYSE: ORCL) falls down to its knees, share dropped over 12.15%...

RTX Corp (NYSE: RTX)...

RTX Corp (NYSE: RTX) experienced a notable decline of -7.22%, amounting to $6.03...

GameStop Corp. (NYSE:GME) Quarter...

GameStop Corp. (NYSE: GME) to announce its second quarter fiscal 2023 results after...

Advanced Micro Devices (NASDAQ:AMD)...

Shares of Advanced Micro Devices (NASDAQ:AMD) drops 0.38% in afterhours in last trading...
HomeTagsDeltacelTM Development Strategy

Tag: DeltacelTM Development Strategy

Kiromic BioPharma, Inc. (NASDAQ: KRBP)...

A clinical-stage fully-integrated biotherapeutics company, Kiromic BioPharma,...

Kiromic BioPharma, Inc. (NASDAQ: KRBP) Receives FDA Validating Written Input on Its DeltacelTM Development Strategy

A clinical-stage fully-integrated biotherapeutics company, Kiromic BioPharma, Inc. (NASDAQ: KRBP) plunged over 15.88% in early trading session on Friday as It announces that the FDA provided validating written input on its DeltacelTM development strategy on October 4, 2022, in response to its Type B Pre-IND meeting request. The purpose of the Pre-IND meeting request was to seek alignment with and obtain FDA guidance on Kiromic's proposed development strategy for Deltacel /KB-GDT for treating subjects with Non-Small Cell Lung Cancer, including chemistry, manufacturing, and controls (CMC), nonclinical studies, and clinical study...

Kiromic BioPharma, Inc....

A clinical-stage fully-integrated biotherapeutics company, Kiromic BioPharma, Inc. (NASDAQ: KRBP) plunged over 15.88% in early trading session on Friday as It announces that the...
spot_img

Create a website from scratch

With Newspaper Theme you can drag and drop elements onto a page and customize them to perfection. Try it out today and create the perfect site to express yourself!